Abstract NAD(P)H: quinone oxidoreductase 1 (NQO1) is a ubiquitous flavoenzyme that catalyzes two-electron reduction of various quinones by utilizing NAD(P)H as an electron donor. Our previous study found that progesterone (PG) can protect cardiomyocytes from apoptosis induced by doxorubicin (Dox). Microarray analyses of genes induced by PG had led to the discovery of induction of NQO1 mRNA. We report here that PG induces NQO1 protein and its activity in a dose-dependent manner. Whereas NQO1 is well known as a target gene of Nrf2 transcription factor due to the presence of antioxidant response element (ARE) in the promoter, PG did not activate the ARE, suggesting Nrf2-independent induction of NQO1. To address the role of NQO1 induction in PG-induced cytoprotection, we tested the effect of NQO1 inducer b-naphthoflavone and inhibitor dicoumarol. Induction of NQO1 by b-naphthoflavone decreased Doxinduced apoptosis and potentiated the protective effect of PG as measured by caspase-3 activity. PG-induced NQO1 activity was inhibited with dicoumarol, which did not affect PG-induced cytoprotection. Dicoumarol treatment alone potentiated Dox-induced caspase-3 activity. These data suggest that while NQO1 plays a role in PG-induced cytoprotection, there are additional components contributing to PG-induced cytoprotection.
Introduction Doxorubicin (Dox), an anthracycline quinone, is used as an antineoplastic agent. While Dox has been substantially prescribed for chemotherapy against hematological cancers such as acute leukemia and lymphomas as well as a wide range of solid tumors including breast, lung, and thyroid carcinoma, the use of this drug is limited due to cardiac toxicity [1] [2] [3] . The clinical manifestations of acute Dox toxicity include hypotension, tachycardia, and electrocardiogram abnormalities. Chronic cardiac toxicity can develop years after Dox therapy, including dilated cardiomyopathy and heart failure. Dox-induced cardiomyopathy often leads to congestive heart failure with poor prognosis. Ultrastructural analyses of biopsy samples obtained from patients with cardiomyopathy after Dox treatment revealed loss of myofibrils, dilation of sarcoplasmic reticulum, cytoplasmic vacuolization, mitochondrial swelling, and increased number of lysosomes [4, 5] . In human endocardial biopsies, contraction and ring formation of nuclei suggestive of apoptosis have been documented within 24 h after Dox injection [6] . When exposed to different concentrations of Dox, cardiomyocytes in culture show a significant increase in the number of apoptotic cells [7] . Our recent work has shown that progesterone (PG) can protect cardiomyocytes from Doxinduced apoptosis [8] .
A substantial amount of evidence suggests that reactive oxygen species (ROS) are intimately involved in the pathogenesis of Dox-induced cardiomyopathy [9, 10] . Dox causes an increased generation of ROS [11, 12] .
Experimental studies have shown that oxidative stress impairs contractile function and can result in myocyte hypertrophy, apoptosis, and necrosis. The heart possesses antioxidant enzymes to detoxify ROS, including superoxide dismutases, catalase, glutathione peroxidases, and NADPH: quinone oxidoreductase 1 (NQO1). Studies have indicated that there is a decrease in antioxidant function with menopause [13, 14] , in parallel with an increased incidence of cardiovascular disease. While many studies have investigated the cardiovascular effects of estrogen on antioxidant enzyme function, very little is known about the cardiovascular effects of PG.
PG secreted by the corpus luteum is responsible for the development of the secretory endometrium. The abrupt drop in PG secretion at the end of the menstrual cycle is the main determinant of the onset of menstruation. The effects of PG are mediated through an intracellular progesterone receptor (PR). The highest concentration of PR appears in the uterus; however, PR has also been found in most tissues including the heart [8, 15] . Our recent work has shown that PG induces the expression of about 180 genes in cardiomyocytes, among which is NQO1 [8] .
NQO1, also known as DT-diaphorase, is ubiquitously expressed among various tissues [16] . As a flavoenzyme that catalyzes two-electron reduction of various quinones utilizing NAD(P)H as an electron donor, NQO1-mediated reduction of quinones into hydroquinones is an important cellular defense mechanism against oxidative stress. NQO1 activity can be inhibited by dicoumarol [3-methylene-bis (4-hydroxycoumarin)], a potent and specific inhibitor that competes with NAD(P)H for binding to NQO1. NQO1 is induced in response to a number of agents including betanaphthoflavone (bNF). The gene contains antioxidant response element (ARE) in the promoter, which is a target of Nrf2 transcription factor that can be activated by a variety of xenobiotics, from oxidants to natural products such as isothiocyanates [17, 18] . There is evidence that induction of NQO1 protects cells against reactive oxygen species [19] . This study tests whether NOQ1 gene induction by PG in cardiomyocytes plays a role in PG-induced cytoprotection.
Materials and Methods

Cell Culture and Treatment of Drugs
Cardiomyocytes were prepared from 1-to 2-day-olds neonatal Sprague-Dawley rats (Harland, Indianapolis, IN) as previously described [7] . The myocytes were seeded at a density of 2 9 10 6 cells per 100-mm dish, 0.3 9 10 6 cells per well of 6-well plates, or 7.5 9 10 4 cells per well of 24-well plates. Cells were cultured in DMEM with 1 mM pyruvate, 10% fetal bovine serum, 100 units/ml penicillin, and 100 units/ml streptomycin for 3-4 days before experiments. For PG treatment, cells were cultured in DMEM containing 0.5% FBS to reduce experimental variations. At 1-3 days after culturing with PG, media were changed to fresh DMEM containing 0.5% FBS for Dox treatment.
RT-PCR
Total RNA extracted using Trizol was used as a template for RT-PCR. Superscript II was used for reverse transcription at 37-50°C for 1 h. The denaturation and primer extension temperatures were 94 and 72°C. The annealing temperature varied depending on the GC content of the primers as suggested by the oligonucleotide synthesis company (Biosynthesis, Lewisville, TX). The products were detected by agarose gel electrophoresis and ethidium bromide staining.
For real-time PCR, total RNA was isolated using the RNeasy Mini kit from Qiagen (Valencia, CA) for the generation of cDNA using random hexamer as a primer and Omniscript Reverse Transcription Kit (Qiagen, Carlsbad, CA). Primers and Taqman Ò probes for rat b-glucosidase were purchased from Assay-on-Demand (Applied Biosystems, Foster City, CA). The real-time PCR was performed using the Taqman Ò Universal PCR Master Mix and the ABI PRISM Ò 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The sequence for forward NQO1 primer was 5 0 CTCGCCTCATGCGTTTT TG and reverse NQO1 primer was 5 0 CCCCTAATCTGAC CTCGTTCAT. Real-time PCR for NQO1 was performed using SYBR green according to the standard curve method.
Western Blot
Cells in 100-mm dishes were lysed by scraping in EB buffer (1% Triton X-100, 10 mM Tris pH 7.4, 5 mM EDTA pH 8.0, 50 mM NaCl, 50 mM NaF, 2 mM Na 3 VO 3 ) with freshly added protease inhibitors: 10 lg/ml aprotinin and 1 mM phenylmethanesulfonyl fluoride. Protein concentration was measured by the Bradford method (BioRad, Richmond, CA). Proteins were separated by SDSpolyacrylamide gel electrophoresis using a mini-Protean II electrophoresis apparatus (Bio-Rad, Richmond, CA) run at 60 V. The separated proteins were transferred to immobilon-P membranes (Millipore, Bedford, MA) by electrophoresis. The membrane was incubated with antibodies against NQO1 (a generous gift from Dr. David Ross) and then secondary antibodies conjugated with horseradish peroxidase. The bound antibodies were detected using an enhanced chemiluminescent reaction.
NQO1 Activity Assay
The assay was performed by modified procedures of Ernster according to published protocols [20] . Briefly, cells were washed with PBS and harvested in a lysis buffer (25 mM Tris pH 7.4 and 125 mM sucrose) and sonicated for 30 s and then centrifuged at 9,0009g for 20 min. The supernatant was transferred to a fresh tube and mixed with 0.2 v/v 0.1 M CaCl 2 in 0.25 M sucrose. The mixture was centrifuged at 27,0009g for 20 min. The supernatant was transferred to a fresh tube. Protein concentration of the samples was determined by the Bradford method (Bio-Rad, Richmond, CA), and 5 mg of proteins for each sample was added to the cuvette containing 1 ml assay buffer (25 mM Tris pH 7.4, 6 mg/100 ml BSA, 10 ll/100 ml Tween-20, 5 lM FAD, 0.2 mM NADH). NQO1 activity was determined using 100 lM 2, 6-dichloroindophenol as the substrate for absorbance at 600 nm. NQO1 activity was calculated as the decrease in absorbance per minute per mg total protein of the sample after addition of 10 -5 M dicoumarol.
ARE Reporter Assay
A 40-base pair sequence from NQO1 gene containing ARE sequence was cloned to drive the expression of Firefly luciferase. The plasmid (0.2 lg, kindly provided by Dr. Jeffery Johnson) was cotransfected with a plasmid of Renilla luciferase under the control of thymidine kinase promoter (0.04 lg) using Fugene 6 transfection reagent (Roche). At 48 h after transfection, cells were treated with PG or H 2 O 2 for the measurements of Firefly versus Renilla luciferase using a Dual Luciferase Assay Kit (Promega) and a Luminometer (Turner Designs).
Caspase Activity Assay
After 16 h of Dox treatment, detached cells were collected by centrifugation and were combined with attached cells from the same well in 6-well plates for caspase assay as described [7] . The cells were dissolved in 250 ll of lysis buffer (0.5% Nonidet P-40, 0.5 mM EDTA, 150 mM NaCl, and 50 mM Tris pH 7.5). An equal volume (50 ll) of cell lysates were incubated for 1 h at 37°C with 40 lM of N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC, Alexis Biochemicals, San Diego, CA) in 100 ll reaction buffer (10 mM HEPES, pH 7.5, 0.05 M NaCl, and 2.5 mM DTT). The released AMC was measured using a 96-well fluorescence plate reader (Cambridge Bioresearch Model 7620) with an excitation wavelength of 365 nm and an emission wavelength of 450 nm.
Statistics
Student's t test was used to compare the means of treated samples to that of control samples. Groups of three or more means were compared using ANOVA with post hoc Bonferroni test.
Results
PG Induces NQO1
Our microarray experiments indicated that PG induces NQO1 mRNA by two fold in primary cultured cardiomyocytes [8] . RT-PCR analyses confirmed that 24-h treatment of 10 lM PG induced the elevation of NQO1 mRNA (Fig. 1a) . Using real-time PCR analyses, we found that PG induced NQO1 mRNA expression by 3.5-fold at 48 h (Fig. 1b) . b-Naphthoflavone (bNF), a known NQO1 agonist used as a positive control, induced NQO1 mRNA by 6.1-fold at 48 h (Fig. 1b) . There was a dose-dependent elevation of NQO1 protein with PG treatment that was significant at 5-10 lM PG (Fig. 2a) . The induction of NQO1 protein with 10 lM PG was detectable within 8 h of treatment and reached the highest at 48 h (Fig. 2b) . Induction of NQO1 gene expression resulted in an increase in the activity of NQO1 enzyme. With PG treatment from 0.5 to 10 lM for 24 h, cardiomyocytes were harvested for the measurements of NQO1 activity in the absence or presence of 10 lM dicoumarol. PG induced NQO1 activity at 5-10 lM. Dicoumarol inhibited the activity of NQO1 induced by PG as expected (Fig. 3) .
NQO1 gene contains ARE in the promoter and has often been used for measuring the activation of Nrf2 transcription factor, which binds to ARE. Using 40-base pair NQO1 promoter sequence containing ARE, we measured ARE activation by PG. While the positive control H 2 O 2 caused threefold induction of ARE activity as shown in luciferase reporter assay, PG did not activate ARE within 8 h (Fig. 4) . Measurements of ARE at later time points up to 24 h did not reveal the activation of ARE by PG (data not shown). These data lead us to exclude the activation of ARE as the mechanism of NQO1 gene induction by PG.
Induction of NQO1 is Necessary but Not Sufficient for Cytoprotection
Cardiomyocytes are adherent in cell culture but undergo cell death when exposed to Dox. We have previously shown that this cell death involves an apoptosis-like mechanism as observed with Annexin V staining, DNA ladder fragmentation, cytochrome C release, and increased caspase-3 activity [7] . PG can attenuate Dox-induced apoptosis [8] . Caspase-3 provides a quantitative measurement of apoptosis. To test whether NQO1 mediates cytoprotection, we pretreated primary cardiomyocytes with various doses of bNF from 0.01 to 20 lM followed by Dox treatment to induce apoptosis. bNF treatment alone attenuated Dox-induced caspase-3 activity in a dose-dependent fashion from 0.1 to 10 lM (Fig. 5a ). When cardiomyocytes were treated with PG in the presence of bNF, a slight enhancement of cytoprotection was observed (Fig. 5b) .
In contrast, incubation of cardiomyocytes with an NQO1 antagonist, dicoumarol, resulted in a modest increase in Dox-induced caspase-3 activity (Fig. 6a) . To determine the importance of NQO1 induction by PG, we tested whether dicoumarol blocks PG-induced cytoprotection. The results show that PG was still able to attenuate Dox-induced caspase-3 activity in the presence of dicoumarol (Fig. 6b) . These data suggest that although inducing NQO1 enhances Fig. 4 Inability of PG to activate ARE in the promoter of NQO1 gene. Primary cultured cardiomyocytes were transfected with ARE Firefly luciferase reporter along with Renilla luciferase for the correction of transfection efficiency. At 48 h after transfection, cells were treated with 10 lM PG for indicated time, or with 10 min of 100 lM H 2 O 2 for harvesting 2 h after to measure for luciferase activities. The means labeled with different letters indicate statistic significance as described in Fig. 3 the cytoprotective effect of PG, inhibiting NQO1 does not block Dox-induced apoptosis.
Discussion
We have previously shown that PG can attenuate Doxinduced apoptosis in cardiomyocytes [8] . The present study characterizes the induction of NQO1 expression by PG and addresses the role of NQO1 in PG-induced cytoprotection. While PG causes a dose-and time-dependent induction of NQO1 protein and its activity, PG did not activate ARE, a well-known cis-element in the promoter of NQO1 gene and mediating NQO1 gene transcription by oxidants and xenobiotics. We found that increasing NQO1 activity by bNF showed some protective effect against Dox-induced apoptosis, whereas inhibiting NQO1 activity by dicoumarol did not affect PG-induced cytoprotection. These data indicate that induction of NQO1 is not the only mechanism underlying the cytoprotective effect of PG.
NQO1 has been previously shown to prevent Dox toxicity by reducing Dox to a more stable hydroquinone [21] . The traditional view of Dox toxicity is that Dox induces a state of oxidative stress through a free radical mechanism. Dox has been shown to be able to produce superoxide anion through redox cycling [11, 12] . Floreani et al. [22] noted that induction of NQO1 by resveratrol in isolated atria resulted in a decrease in toxicity of menadione, a quinone-containing molecule similar to Dox. In our study, induction of NQO1 by bNF resulted in a dose-dependent decrease in Dox-induced apoptosis as measured with caspase-3 activity, supporting NQO1 as a cytoprotective gene.
In addition to detoxifying Dox, NQO1 has been found to be involved in apoptosis through an interaction with p53. Induction of p53 by DNA-damaging agents mediates growth arrest or apoptosis. NQO1 physically interacts with and stabilizes p53 protein [23, 24] . Inhibitors of NQO1, such as dicoumarol and agents disrupting the interaction resulted in an increase in p53 turnover and reduced p53 protein [23, 24] . NQO1 knockout mice have a reduced sensitivity to chemical-induced apoptosis in association with the lack of p53 induction [25] . In cardiomyocytes, . Cells were harvested for the measurements of caspase activity using DEVD-AMC as a substrate as described in the ''Materials and Methods.'' The means labeled with different letters indicate statistic significance as described in Fig. 3 inhibition of NQO1 with dicoumarol potentiates Doxinduced apoptosis, suggesting that NQO1 may protect the cells through a p53-independent mechanism. In menopausal or postmenopausal women, there is a decrease in the activity of various antioxidant enzymes that can be reversed with estrogen and progestin supplementation [26] [27] [28] . The antioxidant potential of estrogen results in part from the hydroxyphenolic structure of its molecule [29] and also from its stimulatory effect on the activity of antioxidant enzymes [28, [30] [31] [32] [33] . PG has an anti-apoptotic effect in the ovary, uterus, breast, and anterior pituitary. PR knockout animals are infertile, and only PR-containing cells are prevented from undergoing apoptosis by PG [34] , suggesting that PR plays a critical role in the anti-apoptotic effect of PG.
In cardiomyocytes, induction of bcl-xL is important for PG-induced cytoprotection [8] . The fact that bcl-xL is a prosurvival factor explains the observation that inhibiting NQO1 did not block Dox-induced apoptosis, since the effect of NQO1 relies on events upstream of bcl-xL and mitochondrial release of cytochrome c. PG treatment of bovine luteal cells was associated with an increase in the expression of anti-apoptotic protein bcl-2, a decrease in the pro-apoptotic protein bax, and a decrease in caspase-3 activity that could be reversed with PR antagonists [35, 36] . With the newly identified plasma membraneassociated progesterone receptor (PGRMC1), Peluso and colleagues found its association with plasminogen activator inhibitor RNA binding protein-1 (PAIRBP1), mediating the anti-apoptotic actions of PG in granulocytes [37] .
Our study is consistent with a few reports in the literature indicating a protective effect of PG. Administration of PG in a trauma-hemorrhage model was shown to increase cardiac output, heart performance, and circulating blood volume [38] . PG has also been shown to induce the expression of heat shock proteins, which are protective against cardiac injury [39] . In considering the benefit of PG, PG receptors have also been discovered in vascular smooth muscle cells [40, 41] and PG administration has been found to lower the blood pressure in humans [42, 43] . Most importantly, PG treatment has been found to exhibit protective effects against brain injury [44] [45] [46] . In an acute global cerebral ischemia model of stroke, PG treatment for 7 days after cardiorespiratory arrest was found to completely prevent neuronal loss [44] . Analysis of postinfarcted regions of the cortex revealed decreased cerebral edema and increased cell survival [44] . PG has been shown to protect against lipid peroxidation in this model [47] . The ongoing phase III clinical trials with PG for the treatment of traumatic brain injury (http://clinicaltrials.gov/ct2/ show/NCT00822900?term=progesterone&rank=14) pave the foundation for future clinical use of PG in preventing myocardial injury.
